gering events or prodromal symptoms. The diagnosis of the non-classical form is based on the exclusion of other causes of syncope and a positive response to tilt table testing [5] . While the tilt table test is the diagnostic gold standard, pharmacologic provocation to increase sensitivity of the test is often employed. The complexity of the pathophysiology of the neurocardiogenic syncope is illustrated by the different types of syncopes as a response to tilt table test: cardioinhibitory with or without assystole, vasodepressor and mixed type [4] . Furthermore, the type of syncope can vary in the same patient from one tilt test to another.
As the authors discuss, the specificity of tilt table testing is high, while the sensitivity and reproducibility varies between studies, often at an unacceptable level. Tilt table testing also has some disadvantages, such as the length of time needed to perform the test and the requirement to have a physician present, especially when provocative pharmacologic interventions are administered [1] . An easily performed and reliable adjunct to tilt table testing would be desirable and would be clinically useful.
Kocabaş et al. propose a novel testing method which is based on a maximal or submaximal exercise test and the heart rate recovery following the exercise. The diagnostic measure is the heart rate recovery index, that is, the difference between the maximal heart rate at peak exercise and the heart rate 1 min after the end of the exercise, at rest. The authors have found that the heart rate recovery index was significantly greater in the neurocardioIn this issue of Cardiology , Kocabaş et al. [1] report a novel method for the diagnosis of neurocardiogenic syncope. Neurocardiogenic syncope is the most common cause of transient loss of consciousness. Other terms that have been used for this condition include vasovagal syncope, vasovagal reflex syncope and neurally mediated syncope. Neurocardiogenic syncope is a reflex response resulting in vasodilation and bradycardia. This is distinctly different from orthostatic hypotension (increase in heart rate and fall in blood pressure) and autonomic failure with a fall in blood pressure and no change in heart rate.
Neurocardiogenic syncope is common in the general population. The Framingham study reports a frequency of 3-3.5%. In the study, the age of subjects ranged between 30 and 62 years at the time of the enrollment, and the follow-up time was 26 years [2] . However, the onset of neurocardiogenic syncope may be seen starting at age 13, and the number of subjects with this condition rapidly increases to a peak during the teenage years [3, 4] . A second peak is observed in subjects older than 70 years [3, 4] . The incidence cited by Kocabaş et al. underestimates the number of subjects with this condition.
Neurocardiogenic syncope can be classified as 'classical' and 'non-classical' [3, 5] . The classical form is triggered by precipitating events such as fear, severe pain, emotional distress, instrumentation or prolonged standing and is associated with typical prodromal syndromes. The classical form can often be diagnosed by history. The non-classical form includes episodes without clear trig- genic syncope group than in the healthy control group. In other words, the drop in heart rate after exercise was greater in the syncope group. Kocabaş et al. determined a cutoff point of 35 beats per minute in the heart rate recovery index between healthy controls and subjects with neurocardiogenic syncope. Having greater than 35 beats per minute, heart rate recovery index had 81% sensitivity and 78% specificity to identify patients with neurocardiogenic syncope. This is comparable to the best reports with tilt table testing. Based on this data and the easily obtainable index, the method has the potential for a supportive role in the diagnosis of neurocardiogenic syncope. Nonetheless, the value of this index has to be tested in a larger clinical population, and be replicated.
When the diagnosis of neurocardiogenic syncope is established, appropriate treatment needs to be administered. The vast majority of subjects experience a single or at most a few episodes and do not need any specific treatment [3] . It is widely accepted that educating these subjects is the most useful therapy [3, 5] . This includes the explanation of the underlying mechanism, reassurance about the benign nature of the episodes, the importance of prodromal symptoms and the use of preventive measures to avoid syncope. Physical counterpressure maneuvers may abort impending neurocardiogenic syncope, these include leg crossing, muscle tensing or isometric arm counterpressure maneuvers [6] . These often require training. Patients should also avoid triggering events, such as volume depletion or prolonged standing. Volume expansion by increasing salt and water intake is advisable.
In a small percentage of the subjects with neurocardiogenic syncope, the syncope presents a recurrent disorder with a significant impact on the quality of life. Treatment is required in these patients to avoid injuries, as well as to be able to continue high-risk activities (such as driving). Pharmacologic treatments, physical training and cardiac pacing have been proposed as treatment options [3] [4] [5] [6] . However, the treatment of these subjects is challenging.
A number of pharmaceutical agents have been used in the treatment of neurocardiogenic syncope. These agents have been reported to be effective in uncontrolled trials or in small controlled trials of short duration. However, several long term placebo controlled trials have not been able to show a benefit of the active drug over placebo [3] .
Beta-blockers failed to be effective in most of the longterm controlled trials. The POST trial reported betablockers to be effective in older patients with neurocardiogenic syncope (age 42 or older) [7] . Several vasoconstrictive drugs have been used, but only etilefrine and midodrine have been evaluated in controlled trials. Etilefrine proved to be ineffective. Midodrine, a direct ␣ 1-receptor agonist and vasoconstrictor, is approved for the treatment of orthostatic hypotension. In 2 small trials on neurocardiogenic syncope, midodrine resulted in more symptom-free days and a better quality of life compared to placebo. Serotonin reuptake inhibitor (paroxetine) has been reported to be effective in 1 small controlled trial. Transdermal scopolamine and disopiramide were reported to be ineffective, clonidine was found not to be superior to metoprolol, while fludrocortison (which acts as an intravascular volume expander) has been effective in children and is under investigation in adults.
Cardiac pacing is one of the most debated therapies for neurocardiogenic syncope. Some believe that there is a need for pacemaker therapy when a positive tilt table test occurs with positive carotid sinus massage in highly symptomatic patients [3] . In other subjects with substantial bradycardia or assystole during tilt table testing, the role of cardiac pacing in the prevention of syncope is not well established. Pacemaker therapy was effective in preventing syncope in clinical trials where the subjects were randomly selected to receive a pacemaker. However, in those trials where each subject received a pacemaker and was randomly selected to have the pacemaker turned on or off, no significant differences were found between the 2 groups in the time of first recurrent episode of syncope or in the frequency of syncope [3] . This data suggest that pacemaker therapy is ineffective and acts as a placebo effect. The significance of the placebo effect is further underscored by a report of the unexpected effectiveness of a diagnostic implantable EKG recorder in the prevention of neurocardiogenic syncope [8] .
Physical training treatments are emerging as a new frontline approach to treatment of neurocardiogenic syncope. Orthostatic training (also called tilt training), regular moderate exercise, and physical counterpressure maneuvers are effective, risk free and perhaps a 'low-cost' treatment method, though training can be expensive [3, 5, 6] .
The treatment of neurocardiogenic syncope is challenging and must be individualized due to the lack of generally acceptable treatment options. Diagnosis is often difficult, and thus the exercise method of Kocabaş et al. may be a useful approach to diagnosis in patients with neurocardiogenic syncope and could be a means of guiding therapy.
